Skip to main content
. 2019 Aug 5;38:338. doi: 10.1186/s13046-019-1336-3

Table 1.

Analyses of time to disease progression in advance GC patients under the treatment of oxaliplatin

Factors N Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Gender
 Female 34 1.140 (0.643–2.022) 0.653
 Male 87
Age
  < 60 51 1.345 (0.799–2.264) 0.265
  ≥ 60 70
Stage
 I & II 61 2.776 (1.627–4.734) < 0.001 2.106 (1.221–3.631) 0.007
 III & IV 60
Metastasis
 No 45 3.978 (2.062–7.675) < 0.001 3.534 (1.818–6.868) < 0.001
 Yes 76
Type
 Diffuse 105 0.658 (0.283–1.571) 0.331
 Intestinal 16
GKN2
 Low (− & +) 87 0.544 (0.215–0.798) 0.008 0.464 (0.239–0.901) 0.023
 High (++&+++) 34

Staining intensity, negative: -, weak positive: +, moderate positive: ++, strong positive: +++